Earnings Surge: Recent posts on X have been buzzing about Progyny, Inc. (PGNY) following its strong Q3 earnings report. The company not only beat expectations but also raised its full-year revenue guidance, sparking lively discussions. Many users are highlighting a significant stock price jump of over 7% as a key point of interest.
Buyback and Growth: Another hot topic on X is Progyny’s announcement of a $200 million share repurchase program. Combined with new client wins and expanded offerings, this has fueled optimism among some who see strong growth potential. The insider purchase of shares worth nearly $2 million by a top executive has also caught attention as a positive signal.
Note: This discussion summary was generated from an AI condensation of post data.
Progyny, Inc. Insider Trading Activity
Progyny, Inc. insiders have traded $PGNY stock on the open market 5 times in the past 6 months. Of those trades, 1 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $PGNY stock by insiders over the last 6 months:
- PETER ANEVSKI (CHIEF EXECUTIVE OFFICER) purchased 79,500 shares for an estimated $1,930,896
- ALLISON SWARTZ (EVP, GC) has made 0 purchases and 2 sales selling 2,997 shares for an estimated $69,152.
- CHERYL SCOTT sold 2,675 shares for an estimated $59,037
- KEVIN K GORDON sold 2,500 shares for an estimated $55,087
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Progyny, Inc. Hedge Fund Activity
We have seen 181 institutional investors add shares of Progyny, Inc. stock to their portfolio, and 145 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- THRIVENT FINANCIAL FOR LUTHERANS added 2,100,560 shares (+3637.3%) to their portfolio in Q3 2025, for an estimated $45,204,051
- FMR LLC added 1,856,486 shares (+39.4%) to their portfolio in Q3 2025, for an estimated $39,951,578
- D. E. SHAW & CO., INC. removed 717,922 shares (-42.7%) from their portfolio in Q3 2025, for an estimated $15,449,681
- BARCLAYS PLC added 696,447 shares (+79.2%) to their portfolio in Q3 2025, for an estimated $14,987,539
- CITADEL ADVISORS LLC added 594,506 shares (+181.6%) to their portfolio in Q3 2025, for an estimated $12,793,769
- POINT72 ASSET MANAGEMENT, L.P. removed 444,739 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $9,570,783
- FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ added 412,395 shares (+33.1%) to their portfolio in Q3 2025, for an estimated $8,874,740
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Progyny, Inc. Analyst Ratings
Wall Street analysts have issued reports on $PGNY in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 08/08/2025
- Leerink Partners issued a "Outperform" rating on 07/08/2025
To track analyst ratings and price targets for Progyny, Inc., check out Quiver Quantitative's $PGNY forecast page.
Progyny, Inc. Price Targets
Multiple analysts have issued price targets for $PGNY recently. We have seen 7 analysts offer price targets for $PGNY in the last 6 months, with a median target of $27.0.
Here are some recent targets:
- Scott Schoenhaus from Keybanc set a target price of $30.0 on 11/12/2025
- Lisa Gill from JP Morgan set a target price of $26.0 on 11/11/2025
- Richard Close from Canaccord Genuity set a target price of $23.0 on 08/20/2025
- Sarah James from Cantor Fitzgerald set a target price of $28.0 on 08/08/2025
- Jailendra Singh from Truist Securities set a target price of $27.0 on 07/17/2025
- Michael Cherny from Leerink Partners set a target price of $28.0 on 07/08/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
